EyePoint Pharmaceuticals has reported positive topline 36-month follow-up data from the second Phase III trial of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18mg three-year micro-insert.
This drug is intended to treat chronic non-infectious uveitis impacting the posterior segment of the eye.
EyePoint Pharmaceuticals president and CEO Nancy Lurker said: “We continue to believe YUTIQ is a differentiated treatment option compared to existing therapies because of its highly efficacious and solid safety profile, coupled with its convenient, single administration and long-term consistent dosing of drug.
“The 36-month results provide additional support in its long-acting potential, a characteristic consistently regarded by treating physicians as a critical treatment advantage. Our commercial efforts are yielding increased reception and adoption from uveitis specialists across the US, as well as positive patient feedback on the YUTIQ product profile.”
This second randomised, double-masked, Phase III trial of YUTIQ saw an enrollment of 153 patients in 15 clinical centres in India. Out of the 153 patients, 101 eyes were treated with YUTIQ, while 52 eyes received sham injections.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAt 36-months, the recurrence rate in YUTIQ randomised eyes was found to be substantially lower than in sham-treated eyes.
Visual acuity gains or losses of three-lines or more were also found to be similar between treatment groups.
Fewer YUTIQ-treated eyes (8.9%) required the assistance of adjunctive intraocular/periocular injection medication for uveitic inflammation as against the sham-treated eyes (51.9%).
Furthermore, 31.7% of YUTIQ treated eyes required the assistance of an adjunctive systemic steroid or immunosuppressant as against 32.7% for sham-treated eyes.
In 75.8% of YUTIQ treated eyes, Macular edema was resolved, while 53.8% of sham-treated eyes had edema recorded at baseline.
At 36 months, mean intraocular pressure (IOP) was 14.8 mmHg in YUTIQ treated eyes and 13.4 mmHg in sham-treated eyes.
In 74.3% of YUTIQ treated eyes, intraocular pressure-lowering drops were used, and 73.1% in sham-treated eyes.
IOP lowering surgeries were carried out in 2% of YUTIQ treated eyes, while it was none in the sham-treated eyes.
By month 36, for patients with phakic eyes, cataracts were extracted from 70.5% of patients administered with YUTIQ and 26.5% of patients administered sham.
YUTIQ was approved by the FDA in October 2018.
